EYPT EyePoint, Inc.
FY2025 10-K
EyePoint, Inc. (EYPT) filed its fiscal year 2025 10-K annual report with the SEC on Mar 5, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biopharma developing sustained intraocular drug delivery therapeutics for serious retinal diseases leveraging proprietary bioerodible Durasert E™ technology
- • New emphasized product: DURAVYU™, a novel multi-mechanism VEGF receptor, PDGF, and IL-6/JAK1 inhibitor in Phase 3 trials for wet AMD and DME, first patient dosed in DME Phase 3 in Feb 2026
Management Discussion & Analysis
- • Revenue $31.4M down 28% YoY from $43.3M; product sales fell 50% to $1.6M, license/collab revenues down 57% to $16.7M, royalty income up 708% to $13.0M
- • Operating expenses $274.8M up 45% YoY from $189.1M; R&D $221.0M up 66%, G&A $51.6M down 1%; operating loss $243.4M vs $145.9M, loss margin ~776% vs 337% (loss/net loss ÷ revenue)
Risk Factors
- • DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
- • Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027
Get deeper insights on EyePoint, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.